Company profile

Arcturus Therapeutics

arcturusrx.comHeadquarters: United States
51-200 employeesProduct Vendor
Arcturus Therapeutics logo

Primary focus

Developing mRNA medicines and vaccines, focused on infectious disease vaccines and rare liver and respiratory diseases.

Why it’s included

The company explicitly develops self-amplifying mRNA vaccines for viral diseases, including pandemic influenza (e.g., 'LUNAR®-H5N1 (ARCT-2304)'), and demonstrates rapid platform adaptation, scalable manufacturing, and formulation technologies directly aligned with the topic.

Relevant capabilities

  • Self‑amplifying RNA vaccine development and clinical evaluation
  • mRNA design and optimization for vaccines and therapeutics
  • Lipid nanoparticle (LNP) formulation and ionizable lipid structure–property design
  • Scalable LNP formulation processes and manufacturing technology transfer
  • Aerosolized/inhaled LNP formulation and device compatibility testing
Commercial sectorNucleic Acid Vaccine Platforms
Technology classesSelf-amplifying RNA (saRNA) vaccines, Lipid nanoparticle (LNP) delivery systems for RNA vaccines, mRNA vaccines (conventional and nucleoside-modified)

Relevant commercial products

  • LUNAR®-FLU (ARCT-2138)
  • LUNAR®-H5N1 (ARCT-2304)
  • KOSTAIVE®
  • Self‑amplifying mRNA COVID‑19 vaccine (clinically evaluated and authorized in select jurisdictions)
  • STARR

Relevant patents

2 families, 5 publications
  • Coronavirus vaccine compositions and methods US-11744887-B2
  • Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines US-12533410-B2

← Back to what’s inside this report